FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2308294549> ?p ?o ?g. }

• W2308294549 endingPage "1935" @default.
• W2308294549 startingPage "1928" @default.
• W2308294549 abstract "Background.Episodes of viremia are common in African antiretroviral therapy (ART) programs. We sought to describe viremia, resuppression, and accumulation of resistance during first-line combination ART (cART) in South Africa. Methods.Retrospective analysis of a cohort receiving zidovudine, lamivudine, and either efavirenz or nevirapine with human immunodeficiency virus (HIV) RNA monitoring every 6 months. We assessed viremia (HIV RNA >1000 copies/mL after initial HIV RNA response) and resuppression (HIV RNA <400 copies/mL after viremia). Genotypic resistance testing was performed using stored plasma on a subset of patients at first detection of viremia and subsequently among patients with persistent viremia. Results.Between 2002 and 2006, 3727 patients initiated cART (median CD4, 147 cells/mm3). Of 1007 patients who developed viremia, 815 had subsequent HIV RNA assays, and 331 (41%) of these resuppressed without regimen switch. At identification of viremia, 45 (66%) of 68 patients had HIV-1 drug resistance, 42 (62%) had nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistance, 25 (37%) had M184V/I, and 4 (6%) had multi-nucleoside analogue drug mutations. By 12 months of persistent viremia among a subset of 14 patients with resistance testing to 12 months, 11 (78%) had nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistance, 8 (57%) had M184V/I, and 2 (14%) had multi-nucleoside analogue drug mutations. Resistance was associated with a reduced probability of resuppression; however, 50% of patients with NNRTI resistance resuppressed while receiving an NNRTI. Conclusions.The majority of patients had NNRTI resistance mutations at detection of viremia. However, 41% resuppressed without regimen switch. Our findings support maximizing first-line use while minimizing risk of significant cross-resistance by implementing intensive adherence support and repeat HIV RNA testing 3–6 months after detecting viremia, with regimen switch only if viremia persists." @default.
• W2308294549 created "2016-06-24" @default.
• W2308294549 creator A5021651811 @default.
• W2308294549 creator A5025743822 @default.
• W2308294549 creator A5026823919 @default.
• W2308294549 creator A5033643317 @default.
• W2308294549 creator A5038341964 @default.
• W2308294549 creator A5047879346 @default.
• W2308294549 creator A5055501691 @default.
• W2308294549 creator A5071106707 @default.
• W2308294549 creator A5076256469 @default.
• W2308294549 creator A5077232684 @default.
• W2308294549 date "2009-12-15" @default.
• W2308294549 modified "2023-10-11" @default.
• W2308294549 title "Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First‐Line Antiretroviral Therapy in South Africa" @default.
• W2308294549 cites W1777183656 @default.
• W2308294549 cites W1971334912 @default.
• W2308294549 cites W1998085351 @default.
• W2308294549 cites W1999859512 @default.
• W2308294549 cites W2002163141 @default.
• W2308294549 cites W2021660989 @default.
• W2308294549 cites W2022805318 @default.
• W2308294549 cites W2029246165 @default.
• W2308294549 cites W2046915735 @default.
• W2308294549 cites W2078262030 @default.
• W2308294549 cites W2088779891 @default.
• W2308294549 cites W2096686776 @default.
• W2308294549 cites W2102741140 @default.
• W2308294549 cites W2115768301 @default.
• W2308294549 cites W2121262079 @default.
• W2308294549 cites W2124943814 @default.
• W2308294549 cites W2125121305 @default.
• W2308294549 cites W2148750104 @default.
• W2308294549 cites W2153766845 @default.
• W2308294549 cites W2170507689 @default.
• W2308294549 cites W2184002906 @default.
• W2308294549 cites W2187955543 @default.
• W2308294549 cites W83241575 @default.
• W2308294549 cites W2414698896 @default.
• W2308294549 doi "https://doi.org/10.1086/648444" @default.
• W2308294549 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2789416" @default.
• W2308294549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19911963" @default.
• W2308294549 hasPublicationYear "2009" @default.
• W2308294549 type Work @default.
• W2308294549 sameAs 2308294549 @default.
• W2308294549 citedByCount "110" @default.
• W2308294549 countsByYear W23082945492012 @default.
• W2308294549 countsByYear W23082945492013 @default.
• W2308294549 countsByYear W23082945492014 @default.
• W2308294549 countsByYear W23082945492015 @default.
• W2308294549 countsByYear W23082945492016 @default.
• W2308294549 countsByYear W23082945492017 @default.
• W2308294549 countsByYear W23082945492018 @default.
• W2308294549 countsByYear W23082945492019 @default.
• W2308294549 countsByYear W23082945492020 @default.
• W2308294549 countsByYear W23082945492021 @default.
• W2308294549 countsByYear W23082945492022 @default.
• W2308294549 crossrefType "journal-article" @default.
• W2308294549 hasAuthorship W2308294549A5021651811 @default.
• W2308294549 hasAuthorship W2308294549A5025743822 @default.
• W2308294549 hasAuthorship W2308294549A5026823919 @default.
• W2308294549 hasAuthorship W2308294549A5033643317 @default.
• W2308294549 hasAuthorship W2308294549A5038341964 @default.
• W2308294549 hasAuthorship W2308294549A5047879346 @default.
• W2308294549 hasAuthorship W2308294549A5055501691 @default.
• W2308294549 hasAuthorship W2308294549A5071106707 @default.
• W2308294549 hasAuthorship W2308294549A5076256469 @default.
• W2308294549 hasAuthorship W2308294549A5077232684 @default.
• W2308294549 hasBestOaLocation W23082945491 @default.
• W2308294549 hasConcept C104317684 @default.
• W2308294549 hasConcept C114851261 @default.
• W2308294549 hasConcept C126322002 @default.
• W2308294549 hasConcept C142462285 @default.
• W2308294549 hasConcept C156719811 @default.
• W2308294549 hasConcept C159047783 @default.
• W2308294549 hasConcept C182707283 @default.
• W2308294549 hasConcept C203014093 @default.
• W2308294549 hasConcept C2522874641 @default.
• W2308294549 hasConcept C2776185481 @default.
• W2308294549 hasConcept C2777351918 @default.
• W2308294549 hasConcept C2777869810 @default.
• W2308294549 hasConcept C2779130552 @default.
• W2308294549 hasConcept C2780216070 @default.
• W2308294549 hasConcept C2780593183 @default.
• W2308294549 hasConcept C2780727368 @default.
• W2308294549 hasConcept C2781413609 @default.
• W2308294549 hasConcept C2781432083 @default.
• W2308294549 hasConcept C2993143319 @default.
• W2308294549 hasConcept C54355233 @default.
• W2308294549 hasConcept C67705224 @default.
• W2308294549 hasConcept C71924100 @default.
• W2308294549 hasConcept C86803240 @default.
• W2308294549 hasConceptScore W2308294549C104317684 @default.
• W2308294549 hasConceptScore W2308294549C114851261 @default.
• W2308294549 hasConceptScore W2308294549C126322002 @default.
• W2308294549 hasConceptScore W2308294549C142462285 @default.
• W2308294549 hasConceptScore W2308294549C156719811 @default.
• W2308294549 hasConceptScore W2308294549C159047783 @default.

• next